| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Research Unit, Department of Medicine, Mayo Medical School Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Michael D. Jensen, M.D., Endocrine Research Unit, 5–164 West Joseph, Mayo Clinic, Rochester, Minnesota 55905.
To determine whether physiological changes in plasma glucagon concentrations are important in regulating basal adipose tissue lipolysis, FFA flux ([l–14C]palmitate) was measured in response to increases and decreases in plasma glucagon. Eight volunteers with insulin-dependent diabetes mellitus (IDDM) and nine healthy nondiabetic volunteers were studied using the pancreatic clamp technique to control plasma insulin, GH, and glucagon concentrations at desired levels. Palmitate flux at the chosen euglucagonemic hormone infusion rates was similar to baseline values (1.73 ± 0.12 vs. 1.75 ± 0.23 and 1.35 ± 0.18 vs. 1.35 ± 0.16 µmol/kg·min, respectively, in IDDM and nondiabetic subjects). No significant changes in palmitate flux occurred in response to glucagon withdrawal or mild (non-diabetic volunteers) or high physiological (IDDM volunteers) hyperglucagonemia. Thus, undei conditions of normal FFA availability, changes in plasma glacagon concentrations within the physiological range have little or no effect on adipose tissue lipolysis.
* This work was supported by USPHS Grants DK-38092, DK-40484, and RR-0585 and the Mayo Foundation.
Received July 16, 1990.
This article has been cited by other articles:
 |
|
 |
|
  N. Rivera, C. A. Everett-Grueter, D. S. Edgerton, T. Rodewald, D. W. Neal, E. Nishimura, M. O. Larsen, L. O. Jacobsen, K. Kristensen, C. L. Brand, et al. A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 743 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Nafikov, B. N. Ametaj, G. Bobe, K. J. Koehler, J. W. Young, and D. C. Beitz Prevention of Fatty Liver in Transition Dairy Cows by Subcutaneous Injections of Glucagon J Dairy Sci, May 1, 2006; 89(5): 1533 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nielsen, N. Moller, S. B. Pedersen, J. S. Christiansen, and J. O. L. Jorgensen The Effect of Long-Term Pharmacological Antilipolysis on Substrate Metabolism in Growth Hormone (GH)-Substituted GH-Deficient Adults J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3274 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Gravholt, N. Møller, M. D. Jensen, J. S. Christiansen, and O. Schmitz Physiological Levels of Glucagon Do Not Influence Lipolysis in Abdominal Adipose Tissue as Assessed by Microdialysis J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2085 - 2089. [Abstract] [Full Text]
|
|
|
|
|
|
E. Bertin, P. Arner, J. Bolinder, and E. Hagström-Toft Action of Glucagon and Glucagon-Like Peptide-1-(7-36) Amide on Lipolysis in Human Subcutaneous Adipose Tissue and Skeletal Muscle in Vivo J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1229 - 1234. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Shah, A. Basu, R. Basu, and R. Rizza Impact of lack of suppression of glucagon on glucose tolerance in humans Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E283 - E290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Donahoo, D. R. Jensen, T. J. Yost, and R. H. Eckel Isoproterenol and Somatostatin Decrease Plasma Leptin in Humans: A Novel Mechanism Regulating Leptin Secretion J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4139 - 4143. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
